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Background. Respiratory syncytial virus (RSV) is an important cause of infant morbidity and mortality and a potential target 
for maternal immunization strategies. However, data on the role of RSV in young infant deaths in developing countries are limited.
Methods. We conducted a community-based mortality surveillance from August 2018–March 2020 for infants ≤6 months in 
Karachi, Pakistan. We tested (reverse transcription–polymerase chain reaction) nasopharyngeal swabs from deceased infants for pres-
ence of RSV. We performed verbal autopsies and calculated odds of RSV-associated mortality with 95% CIs and used multivariable 
logistic regression to evaluate associations.
Results. We collected 490 nasopharyngeal specimens from 1280 eligible infant deaths. There were 377/490 (76.9%) live births 
and 14/377 (3.7%; 95% CI: 1.8–5.6) were RSV positive. Most deaths occurred in neonates (254/377; 67.4%), males (226/377; 59.9%), 
and respiratory illnesses (206/377; 54.6%). Postneonatal age (10/14, 71.4%; OR: 5.5; 95% CI: 1.7–18.0), respiratory symptoms (12/14, 
85.7%; OR: 5.2; 1.2–23.7), and high RSV season (9/14, 64.3%; OR: 4.4; 1.4–13.3) were associated with RSV mortality. In multivariable 
logistic regression analysis, respiratory symptoms (OR: 6.6; 95% CI: 1.3–32.5), RSV seasonality (6.1; 1.8–20.4), and age (9.2; 
2.6–33.1) were significant predictors of RSV-associated mortality.
Conclusions. RSV has a significant mortality burden in early infancy in Karachi, Pakistan. Age, RSV seasonality, and respira-
tory symptoms were significant predictors of RSV-associated mortality. Our findings have implications for clinical management of 
young infants with cold-like symptoms, policy development, and research regarding maternal immunization against RSV during 
pregnancy, in resource-constrained, low-income, and vaccine-hesitant populations.
Keywords.  respiratory syncytial virus; maternal vaccine; community-based mortality surveillance; verbal autopsy.
Respiratory syncytial virus (RSV) is a respiratory pathogen with an 
initial global burden of disease estimates indicating a moderate to 
high burden in developing countries, specifically among young in-
fants [1–4]. This virus is a potential target for maternal immuniza-
tion strategies to prevent disease and early death in young infants. 
However, due to a lack of definitive evidence, the role of RSV in neo-
natal and young infant mortality in low- and middle-income coun-
tries is not known [5]. Moreover, most current studies estimate RSV 
disease burden only in terms of facility-based (hospital or clinic) 
deaths and hospital-acquired infections. Thus, there is a know-
ledge gap regarding the proportion of community-based deaths 
due to RSV. Furthermore, there are many challenges to generating 
high-quality evidence for the role of RSV in infant mortality, such 
as lack of resources for hospital and community surveillance and 
diagnostics and difficulty in obtaining specimens in populations 
where burial occurs within hours after death [6]. Therefore, there 
are limited direct data on the incidence and severity of RSV and 
the associated early deaths in specific populations [1, 3], resulting in 
insufficient evidence to inform policy considerations for maternal 
and childhood immunization schedules [7].
Pakistan has one of the highest infant mortality rates globally 
due to multiple causes, but little is known about the RSV burden 
in infant mortality [8]. The primary objective of this study was to 
assess and analyze the burden and determinants of RSV mortality 
in infants in the urban areas of Karachi, Pakistan. We conducted a 
community-based mortality surveillance study to obtain more ac-
curate estimates of RSV-associated deaths in young infants in these 
areas. This is a seminal community-based RSV mortality study in 
Pakistan, made possible due to close liaison with the communities 
to collect nasopharyngeal swab samples from deceased infants.
METHODS
This was an observational community-based mortality surveil-
lance study conducted in 4 peri-urban low-income settlements 
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(Rehri Goth, Ibrahim Hyderi, Bhains Colony, and Ali Akbar 
Shah) in Karachi, Pakistan. The overall population of the catch-
ment area is approximately 249 128, with a cohort of approxi-
mately 7525 new births per year [9].
Data were collected from August 2018 to March 2020. The 
primary outcome measure was prevalence of laboratory-
confirmed (reverse transcription–polymerase chain reac-
tion [RT-PCR]) RSV infection in nasopharyngeal specimens 
from recently deceased infants younger than 6 months. The 
study enrollment inclusion criteria comprised stillborn or re-
cently deceased infants under 6 months of age in the catch-
ment areas. Parents or other caregivers gave informed verbal 
consent for a nasopharyngeal swab collection from their 
deceased infant at the household preferably before ritual 
cleansing and shrouding, and before burial.
Prior to the onset of the surveillance phase, we conducted 
a formative phase where we explored the acceptance of study 
procedures within the communities and assessed the benefits 
to families of deceased infants for participating in the study. We 
obtained approval and religious rulings from religious scholars 
that collecting specimens via nasopharyngeal swabs after death 
and before burial is religiously acceptable in the context of the 
Islamic, Christian, and Hindu faiths. Infant death alerts were 
conveyed to the team from key community stakeholders, such 
as religious leaders, traditional birthing attendants, and grave-
yard personnel.
Upon receiving a death alert from a key community partner 
or community member, the RSV study team mobilized from the 
primary health center at the field site to the identified house-
hold of the deceased infant. Due to the religious beliefs of pre-
dominantly Muslim communities, burial of the deceased occurs 
as soon as possible. Hence, there was a short time window for 
enrollment before the ritual bathing, shrouding, and burial of 
the infant. A 24 × 7 surveillance system was established to mo-
bilize the study team to approach a household within 25 min-
utes of receiving a death alert.
As Muslim burials generally occur within 24 hours of death and 
the staff received most alerts within 1 hour of the infant’s death, we 
had no concerns about the viability of specimens for collection. 
The nurse performing the nasopharyngeal specimen collection 
donned a surgical mask and clean gloves to minimize exposure. 
Laboratory staff were trained in specimen testing methods for 
Figure 1. Cohort diagram on infant mortality and data collected and tested for RSV from August 2018 to March 2020 in Karachi, Pakistan. Inclusion criteria were deceased 
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RSV. After obtaining verbal consent from the deceased infant’s 
parents/caregivers and completing the Case Record Form (see 
Supplementary Material), trained personnel collected a nasopha-
ryngeal swab from each nostril using Pernasal Dacron swabs. The 
swab was inserted nasally and advanced along the floor of the 
nose until it reached the nasopharynx and held against the poste-
rior nasopharynx for a few seconds, based on Centers for Disease 
Control and Prevention (CDC) guidelines [10], before removal. 
The first swab was immediately placed in a Universal Transport 
Media (UTM) tube, then placed on cold packs or in wet ice (~2–
4°C) to prevent loss in viral titer. The second swab was immedi-
ately placed in semi-solid Regan-Lowe transport medium, then 
placed on cold packs or in wet ice (~2–4°C) to prevent loss in bac-
terial titer (for a separate pertussis study not included in this man-
uscript). The samples were stored in UTM tubes and transported 
to the laboratory. Transport to the Aga Khan University Infectious 
Disease Research Laboratory occurred 3 times a day: morning, af-
ternoon, and evening. During transport, the sample was held at 
2–4°C. It was stored at −70°C or lower upon receipt.
Storage and Archiving
Nasopharyngeal specimens were stored at 70°C or lower prior 
to nucleic acid extraction until sufficient samples were available 
for batch testing. Nucleic acid was extracted from frozen ali-
quots using QIAamp Viral RNA Mini Kit (Qiagen).
Laboratory Tests for Primary Confirmation of Respiratory Syncytial Virus
The extracted nucleic acids (from a Roche MagNApure compact 
automated system) were used for 1-step real-time PCR for RSV 
detection, using a Qiagen 1-step RT-PCR kit. Real-time RT-PCR 
assays were performed with primers and probes for RSV, using 
the CDC protocol [11]. All assays were run with positive controls 
(RSV-RNA), negative controls (nuclease-free water), and in-
ternal positive controls (RNAseP) for quality-control purposes.
Home Visits and Cause of Death Consultation
A psychologist trained the field team in grief support and com-
munication skills to conduct home visits for bereaved parents 
at the time of and up to 2 months after the infant’s death. The 
World Health Organization (WHO) verbal and social autopsy 
Figure 2. Number of deceased infants enrolled and RSV-positive cases by month and year. This shows trends in enrollment between August 2018 and March 2020 with 
number of RSV-positive cases per month. August 2018 to December 2018 was the pilot surveillance phase. The monsoon season (lots of rain) in Karachi, Pakistan, is between 
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tool was administered during grief-support home visits within 
a week of enrollment. A cause of death report containing verbal 
and social autopsy findings and laboratory-confirmed PCR re-
sults for RSV was shared with enrolled parents alongside con-
tinuous community engagement activities.
Verbal Autopsy—Identifying Cases and Controls
To determine the cause of death, the following was considered: 
(1) nasopharyngeal swab test results, (2) medical records of 
symptoms (when available), and (3) verbal and social autopsy. 
Symptoms obtained through verbal autopsy as well as medical 
records, when available, were considered to determine the likely 
cause of death. Cases were deceased infants who had respiratory 
symptoms as per acute lower respiratory infection (ALRI) cri-
teria (cough, wheezing, rhonchus, crackles, etc). Controls were 
deceased infants who did not have any of the defined respira-
tory symptoms.
Statistical Analysis
To determine RSV burden, we calculated crude RSV mortality 
proportions and the odds of having laboratory-confirmed 
RSV among cases and controls of deceased infants captured 
through our surveillance system. Our symptom-based case 
definitions for respiratory disease cases was a deceased live-
birth infant who had at least 1 of these respiratory symp-
toms that occurred within 2 weeks immediately preceding 
death, with no asymptomatic period between symptom onset 
and death: (1) cough, (2) difficulty breathing, (3) chest wall 
indrawing, (4) wheezing, (5) rhonchus, or (6) crackles when 
breathing and any one of the very severe symptoms (head-
nodding, lethargy, convulsions, cyanosis, difficulty breast-
feeding, or vomiting) [9, 12]. Very severe ALRI includes 
presence of respiratory symptoms plus unconsciousness, 
poor feeding, lethargy, and convulsions. Controls were de-
fined as deceased live-birth infants who did not meet the 
symptom-based case definition above.
To determine predictors of RSV mortality, we compared the 
distribution of covariates such as hospital deaths versus commu-
nity deaths and gender, age, or seasonality among infants with 
and without laboratory-confirmed RSV (controls) using chi-
square tests and odds ratios (ORs). Since we did not have access 
to the medical records of most of the deceased infants to deter-
mine the details of length of hospital stay for the entire sample, 
we defined hospital deaths as deaths that occurred inside a ter-
tiary care hospital, regardless of duration of time in the hospital. 
Community deaths were defined as infants who died either 
on the way to the hospital, in the traditional birth attendant’s 
home, at the clinic, at home, or in a community-based health 
center. Age was categorized as 0–3  months and 4–6  months, 
as well as neonatal (0–28 days old) and post-neonatal (29 days 
and older) for analysis. Stillborn infants were not included in 
the analyses as we would not expect to see any RSV in them 
(never exposed to RSV). RSV seasonality in Pakistan was de-
fined based on a prospective surveillance study conducted at 
the Aga Khan University Hospital in Karachi, Pakistan [13]. 
RSV is identified year-round in Pakistan but is most prevalent 
during the rainy season, which is from August to October with 
a peak in September. For analyses, we classified RSV seasonality 
as “high” (August to October) and “low” (November to July). 
Multivariable logistic regression was used to assess the associ-
ation of these covariates on RSV positivity among deceased in-
fants. This will provide key information regarding the extent to 
Table 1. Clinical and Demographic Characteristics of the Deceased Live-
Birth Infants: August 2018–March 2020, Karachi, Pakistan
Variable
RSV Status
Negative, n (%) Positive, n (%) Total, n (%)
Total, n (%) 363 (96.3) 14 (3.7) 377 (100.0)
Age at death    
 0–3 months 320 (88.2) 12 (85.7) 332 (88.1)
 ≥3 months 43 (11.8) 2 (14.3) 45 (11.9)
Age at death    
 Neonatal: 
0–28 days
250 (68.9) 4 (28.6) 254 (67.4)
 Non-neonatal: 
≥29 days
113 (31.1) 10 (71.4) 123 (32.6)
Sex    
 Female 146 (40.2) 5 (35.7) 151 (40.1)
 Male 217 (59.8) 9 (64.3) 226 (59.9)
Study site    
 Ali Akbar Shah 
Goth
102 (28.1) 10 (71.4) 112 (29.7)
 Bhains Colony 107 (29.5) 2 (14.3) 109 (28.9)
 Ibrahim Hyderi 73 (20.1) 2 (14.3) 75 (19.9)
 Rehri Goth 81 (22.3) 0 (0.0) 81 (21.5)
Place of death    
 Community 185 (51.0) 4 (28.6) 189 (50.1)
 Hospital 178 (49.0) 10 (71.4) 188 (49.9)
Symptom-based 
case definitions
   
 Case 194 (53.4) 12 (85.7)  206 (54.6)
 Control 169 (46.6) 2 (14.3)  171 (45.4)
Season of illness 
and death
   
 Low (November 
to July)
257 (70.8) 5 (35.7) 262 (69.5)
 High (August to 
October)
106 (29.2) 9 (64.3) 115 (30.5)
ALRI 
classificationa
   
 ALRI 84 (23.1) 4 (28.6) 88 (23.3)
 Severe ALRI 19 (5.2) 3 (21.4) 22 (5.8)
 Very severe 
ALRI
91 (25.1) 5 (35.7) 96 (25.5)
 No respiratory 
symptoms
169 (46.6) 2 (14.3) 171 (45.4)
Abbreviations: ALRI, acute lower respiratory infection; RSV, respiratory syncytial virus.
aALRI, cough or difficulty breathing with increased respiratory rate for age; Severe ALRI, 
ALRI with wheeze and chest wall indrawing; Very severe ALRI, ALRI with at least 1 danger 
sign (eg, cyanosis, difficulty in breastfeeding or drinking, vomiting, convulsions, lethargy, 
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which severe disease (eg, requiring care in a hospital prior to 
death) is associated with RSV positivity, while adjusting for the 
presence or absence of other covariates.
Approval from the Ethical Review Committee/Institutional 
Review Boards (IRBs) of Yale University and Aga Khan 
University was obtained. Study protocol, all data-collection in-
struments, and consent forms (into English as well as in local 
languages) were also approved by both institutions’ IRBs.
RESULTS
Of 1280 eligible infant deaths that occurred between August 
2018 and March 2020 in the catchment areas, 490 nasopha-
ryngeal specimens were obtained; 113 of 490 (23.1%) were 
stillborn and 14 of 377 (3.7%; 95% confidence interval [CI]: 
1.8–5.6%) live-birth infant specimens tested positive for RSV. 
Figure 1 shows the cohort diagram. Most of the deceased live-
birth infants were males (226/377; 59.9%) and aged 0–3 months 
old (332/377; 88.1%) or neonates (254/377; 67.4%). The mean 
age of the population studied was 30.3 months (95% CI: 28.7–
31.9 months) and the median age was 6.0 months. Figure 2 in-
dicates trends in enrollment between August 2018 and March 
2020 with RSV seasonality.
Attribution of Respiratory Deaths
The proportion of deceased infants with laboratory-confirmed 
RSV was 14 of 377 (3.7%) (Table 1). There was a similar 
proportion of deaths in the community or hospital; however, 
most of the RSV cases (10/14; 71.4%) died in a hospital. It is 
important to note that, for some of the infants whose medical 
records were available, while they did not spend up to 24 to 48 
hours in the hospital where they died, they presented at several 
hospitals for the fatal illness. Two of the RSV-positive cases who 
died in the hospital within 24 hours of hospitalization were ad-
mitted to the intensive care unit prior to death.
To compare the distribution of covariates among deceased 
infants with laboratory-confirmed RSV status vs no RSV, we 
calculated odds ratio (see Table 2). While the majority (67.4%; 
254/377) of the deceased live-birth infants died during the ne-
onatal period, most of the RSV-positive cases (71.4%; 10/14) 
were among infants who died after the neonatal period (OR: 
5.5; 95% CI: 1.7–18.01). Deceased infants who had respiratory 
symptoms during fatal illness were more likely to test positive 
for RSV versus those who had no respiratory symptoms during 
fatal illness (12/14, 85.7%; OR: 5.2; 95% CI: 1.2–23.7). Infants 
who died during the high-RSV season were more likely to test 
positive for RSV compared with those who died during the low-
RSV season (64.3%, 9/14; OR: 4.4; 95% CI: 1.4–13.3).
In multivariable logistic regression, we found that age 
(>28  days) (OR: 9.2; 95% CI: 2.6–33.1), having respiratory 
symptoms (OR: 6.6; 95% CI: 1.3–32.5), and RSV seasonality 
(OR: 6.1; 95% CI: 1.8–20.4) were significant predictors of testing 
RSV positive (Table 3).
Table 2. Comparing Distribution of Covariates Among Deceased Infants with Laboratory-Confirmed Respiratory Syncytial Virus Status (Chi-Square)
Variable Number of Observations OR 95% Confidence Limits P
Symptom-based case definitions for 
respiratory disease (case vs control)
377 5.2 1.2–23.7 .02
Place of death (hospital vs community) 377 2.6 .8–8.4 .10
Gender (male vs female) 377 1.2 .4–3.7 .74
Age (0–3 months vs ≥3 months) 377 1.2 .3–5.7 .78
Age (non-neonatal vs neonatal) 377 5.5 1.7–18.01 .0016
Seasonality (high vs low) 377 4.4 1.4–13.3 .0051
Number of observations shows the total number of enrolled live-birth infants tested for RSV = 377. The outcome is RSV-positive status. Abbreviations: OR, odds ratio; RSV, respiratory 
syncytial virus.
Table 3. Multivariable Logistic Regression Model of Prediction of Respiratory Syncytial Virus Positivity in Infants Who Died from August 2018 to March 
2020 in Karachi, Pakistan
Variables Estimate Standard Error Wald Chi-Square Pr > ChiSq OR 95% CI
Intercept –9.9 2.0 24.6 <.0001   
Age (non-neonate vs neonate) 2.2 0.7 11.6 .0007 9.2 2.6–33.1
Sex (male vs female) 0.3 0.6 0.2 .6255 1.4 .4–4.5
Symptom-based case definitions for 
respiratory disease (case vs control)
1.9 0.8 5.4 .0203 6.6 1.3–32.5
Place of death (hospital vs community) 1.0 0.6 2.5 .1167 2.7 .8–9.5
Season (high vs low) 1.8 0.6 8.6 .0034 6.1 1.8–20.4
The number of enrolled live birth infants tested for RSV = 377, chi-square = 28.9, df = 5, P = .0001. Probability model shows RSV status = positive; convergence criterion (GCONV = 1E-8) 
satisfied. References: Age: 0–3 months; Sex: female; Cases: acute lower respiratory infection; Place of death: community; and Seasonality: low. Abbreviations: CI, confidence interval; OR, 
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DISCUSSION
This is the first community-based study examining RSV mor-
tality in young, vulnerable infants in Pakistan. This is a seminal 
community-based, real-time surveillance study documenting 
a moderate to high burden of RSV mortality in young infants. 
We found the burden of infant mortality attributed to RSV in 
Karachi, Pakistan, to be similar to the systematic review find-
ings by Nair et al [3] of 2.1% (1.6–2.2%) for children aged 1 year 
or younger in developing countries or 2.2% (1.8–2.7%) for 
children aged 0–5 months in developing countries by Shi et al 
[1]. This indicates a need for development of vaccines for RSV. 
Most deaths occurred among infants aged 28 days and older or 
0–3 months old. This finding is important because maternally 
acquired RSV antibodies at birth predict protection from RSV 
in infants in the first 3–6 months of an infant’s life [14]. This has 
implications for maternal immunization against RSV during 
pregnancy [15]. Furthermore, our findings are in line with 
studies indicating that RSV incidence and mortality propor-
tion increase during the RSV high season [16]. Moreover, the 
majority of the RSV-positive cases had respiratory symptoms 
during fatal illness. This is especially important considering that 
many respiratory infections such as influenza, adenovirus, or 
rhinovirus often present with similar (cold-like) symptoms. In 
young infants, RSV infections develop into serious lower respi-
ratory tract diseases (bronchiolitis and pneumonia) with long-
term sequelae (wheeze, cough, asthma, pulmonary dysfunction, 
bronchial reactivity, and acute respiratory disease), which may 
require oxygen, intubation, and/or mechanical ventilation, or 
worse, death [17]. This has implications for the clinical manage-
ment of young infants with cold-like symptoms. During high-
RSV season, there should be a high index of suspicion for RSV.
Symptom-based case definition of respiratory disease and com-
munity surveillance allowed us to collect data on infants who had 
never been to a hospital and therefore never identified as a case, as 
well as infants who may have had misclassified hospital outcomes 
or comorbid conditions that overshadowed the RSV diagnosis 
(such as congenital malformations). Community engagement and 
support from religious and community leaders and community 
religious buy-in through supporting religious rulings allowed us 
to conduct 24/7 surveillance and obtain consent for specimen col-
lection in a timely, sensitive manner. In such low-income com-
munities, home/community-acquired RSV infection may never 
be tested or treated in a hospital. Therefore, hospital-based data 
for RSV infection and mortality may not be entirely representative 
of the true prevalence. In this study, 4 of the 14 RSV-positive cases 
did not seek care in a hospital for their fatal illness.
Limitations include the unavailability of access to med-
ical records for some of the hospitalized deceased infants. 
Approaching households and obtaining consent in high-refusal 
areas was a data-collection challenge that was overcome with 
community-based study advocacy strategies. We collected data 
over multiple high seasons (2018–2020); however, comparisons 
could not be made between the 3 years since the first high season 
(2018) was a pilot phase with few enrollments and the third high 
season (2020) was interrupted by the coronavirus disease 2019 
(COVID-19) pandemic. The 2019 high season captured the ma-
jority of total enrollments (deaths and cases), indicating that 
overall mortality increases during the RSV high season.
Ongoing surveillance of the community-based RSV infant mor-
tality study includes minimally invasive tissue sampling of lung and 
thorax specimens to further improve classification of upper respira-
tory tract infections, including RSV. As neonates and young infants 
have been found to be particularly vulnerable, this study has sub-
stantive implications for policy development and research regarding 
maternal immunization against RSV, specifically in resource-
constrained, low-income, and vaccine-hesitant populations.
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